Protect muscle on GLP‑1s
If you’re losing weight on GLP‑1 drugs, the leading advice is to actively protect muscle by prioritizing regular strength training and matching nutrition, rather than assuming fat loss alone is the goal. (fitandwell.com) Experts warn that modest lean‑mass loss is common with medical weight loss and bariatric surgery alike, so protein intake and resistance work are practical defenses for athletes and active people. (fitandwell.com)
People taking glucagon-like peptide 1 drugs can lose muscle for the same reason a house loses furniture during a fast move: when body weight drops quickly, the body does not sort every pound into “fat only.” Reviews in 2025 said the tradeoff is real enough that preserving skeletal muscle should be part of treatment, not an afterthought. (nature.com) Glucagon-like peptide 1 drugs work by copying a gut hormone that slows stomach emptying and cuts appetite, so many patients eat much less without white-knuckling every meal. The better-known names are semaglutide and tirzepatide, sold in obesity care as Wegovy and Zepbound. (mayoclinic.org) Lean mass is the bucket that includes muscle, organs, bone, and body water, so a scan that shows “lean mass loss” is not saying every lost pound was contractile muscle. But muscle is the part that helps you climb stairs, carry groceries, and keep resting energy use higher. (jamanetwork.com) In the STEP 1 semaglutide trial, a body-composition subgroup showed that total lean body mass fell along with fat mass over 68 weeks, even as the proportion of lean mass relative to total body weight improved. That is the pattern doctors keep emphasizing: better body composition overall, but still some absolute lean-mass loss. (nejm.org) In the SURMOUNT-1 tirzepatide trial, fat mass dropped by about three times as much as lean mass in a body-composition analysis. That means most of the lost weight was fat, but not all of it. (nejm.org) A 2025 clinical cohort study comparing bariatric surgery with semaglutide and tirzepatide found the same broad pattern over 24 months: substantial fat-mass loss, modest fat-free-mass loss, and a better ratio of fat-free mass to fat mass. The message was not “these drugs uniquely waste muscle,” but “weight loss usually includes some lean tissue unless you work against it.” (jamanetwork.com) The practical defense starts with resistance training, which means making muscles push against load from dumbbells, machines, bands, or body weight. A 2025 JAMA Internal Medicine viewpoint on prescribing these drugs said clinicians should pair them with physical activity and nutrition strategies to help preserve lean body mass. (jamanetwork.com) Protein is the second half of the plan, because muscle is rebuilt from amino acids the way a brick wall is rebuilt from bricks. Cleveland Clinic’s 2025 guidance for patients on semaglutide said rapid weight loss can reduce muscle mass, and it pointed to protein intake plus strength training as the main countermeasures. (clevelandclinic.org) This matters more for older adults because age-related muscle loss already starts creeping up by midlife, and losing additional strength during weight loss can hit balance and mobility faster. The 2025 Nature comment warned that skeletal-muscle loss could undercut metabolic and functional gains if treatment focuses only on the scale. (nature.com) It also matters for active people who care about performance, because eating too little protein while cutting calories can leave workouts flat and recovery slow. The current advice is not to stop medical weight loss, but to treat strength sessions and protein targets as part of the prescription, the same way you would not buy a car and ignore the brakes. (jamanetwork.com)
